Form 4: Amgen EVP James Bradner Awarded Major Equity Grants

Amgen's EVP of Research and Development, James Bradner, received over 25,000 equity-based awards, including stock options and restricted stock units, as part of the company's long-term incentive plan.

Summary

• James E. Bradner, EVP of Research and Development, was granted 3,337 Restricted Stock Units (RSUs) on May 5, 2026.
• Bradner also received 21,773 non-qualified stock options with an exercise price of $329.59 per share.
• A total of 407 shares were disposed of on May 6, 2026, at a price of $329.59 to satisfy tax withholding obligations.
• The equity awards are scheduled to vest in four equal annual installments of 25% each, beginning May 5, 2027.
• Following these transactions, the reporting person directly owns 30,462 shares of common stock, which includes 1,332 dividend equivalents.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it confirms the continued alignment and retention of key scientific leadership through standard incentive structures.

Positives

• Significant equity grants align the interests of the head of Research and Development with long-term shareholder value.
• The ten-year term of the stock options suggests a long-term commitment to the company's growth trajectory.
• The inclusion of dividend equivalents ensures the executive's compensation reflects the total return provided to shareholders.

Negatives

• The disposal of 407 shares, while for tax purposes, represents a minor immediate reduction in direct ownership.
• Future vesting of 25,110 total units/options will result in minor share dilution for existing shareholders.

Risks

• The ultimate value of these compensation awards is contingent upon the company's stock price exceeding $329.59 over the next decade.
• Executive retention is tied to the four-year vesting schedule; departure prior to 2030 would result in forfeiture of unvested portions.

Future Outlook

The executive's compensation is structured to reward long-term performance, with vesting occurring through May 2030 and options remaining valid until May 2036, signaling confidence in the company's long-term R&D pipeline.

Industry Context

StockSavvy.ai notes that high-value equity grants for R&D leadership are standard practice in the biotechnology sector to ensure continuity in drug development cycles that often span a decade or more.

Comparison to Industry Standards

• The four-year vesting period is consistent with industry peers such as Gilead Sciences and Vertex Pharmaceuticals.
• The use of a 10-year option term is a standard benchmark for S&P 500 healthcare companies to incentivize long-term strategic execution.

Stakeholder Impact

• Shareholders may see minor dilution as these equity awards vest and options are exercised over the next several years.
• Employees and partners may view the significant grant to the R&D head as a sign of stability in the company's research direction.

Next Steps

• First 25% tranche of RSUs and options to vest on May 5, 2027.

Key Dates

Recommendation

This filing details routine executive compensation and does not provide new material information regarding the company's operational performance or financial health that would warrant a change in investment rating.

Keywords

Amgen, AMGN, Executive Compensation, Insider Trading, Stock Options, Restricted Stock Units, Biotechnology, James Bradner